Foundayo (Orforglipron) FDA Approval: What the New Oral GLP-1 Pill Means
The first oral GLP-1 weight-loss pill with no food or water restrictions. What ATTAIN-1 data showed, how dosing works, and who it's for.
On April 1, 2026, the FDA approved Foundayo (orforglipron) — the first oral GLP-1 medication for weight loss that can be taken any time of day, with or without food. Approved just 50 days after filing under the FDA's new Commissioner's National Priority Voucher program, it's the fastest approval of a new molecular entity since 2002.
Foundayo is a daily pill, not an injection. It's a small-molecule drug, not a peptide. And unlike oral Wegovy (which requires fasting and water restrictions), Foundayo has no food or water timing rules. Here's what patients and prescribers should know as it rolls out.
What Is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. It's described as a "small molecule non-peptide" — which matters because peptide drugs (like semaglutide) are fragile and must be injected or taken with strict food-and-water restrictions to survive digestion. Small molecules are more chemically stable, which is why Foundayo can be taken any time of day without the fasting window that oral Wegovy requires.
The drug was originally discovered by Chugai Pharmaceutical and licensed by Lilly in 2018. It activates only the GLP-1 receptor (not GIP, unlike tirzepatide, and not glucagon, unlike retatrutide). This single-pathway mechanism produces less weight loss than dual or triple agonists — but the tradeoff is oral convenience and broader accessibility.
The Clinical Data: ATTAIN-1
Foundayo's approval was based primarily on ATTAIN-1, a Phase 3 trial in adults with obesity. Key findings at 72 weeks:
- Highest dose (36 mg): 12.4% average weight loss among trial completers (27.3 lbs)
- All participants (regardless of completion): Average loss of about 25 pounds
- Placebo group: About 2.2 lbs lost
- Cardiometabolic markers: Reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses
For comparison: Wegovy produces around 15% average weight loss at the 2.4 mg injectable dose; Zepbound produces about 20% at the 15 mg dose. Foundayo's 12.4% places it below injectable GLP-1s but above oral Wegovy's highest-dose results (~16.6% in OASIS 4 — though direct comparisons across trials aren't apples-to-apples).
Side Effect Profile
Typical GLP-1 side effects: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, fatigue, belching, heartburn, gas, and hair loss. The FDA label includes the standard boxed warning for thyroid C-cell tumors — Foundayo should not be used in patients with personal or family history of medullary thyroid cancer, or in those with Multiple Endocrine Neoplasia syndrome type 2.
The FDA label specifies that Foundayo should not be used with other GLP-1 receptor agonists. If you're already on Wegovy, Zepbound, Ozempic, or Mounjaro, you cannot add Foundayo on top — you would need to switch. Discuss any transition with your prescriber.
Who Is It For?
Foundayo is FDA-approved for adults with:
- Obesity (BMI ≥ 30), or
- Overweight (BMI ≥ 27) with at least one weight-related medical condition (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
It is used alongside a reduced-calorie diet and increased physical activity — same lifestyle adjunct requirement as every other GLP-1 approval. It is not approved for pediatric use.
Dosing
Foundayo comes in six doses ranging from 0.8 mg to 17.2 mg (the trial's "36 mg" referred to an earlier dosing nomenclature; the final commercial doses are titrated up from the lowest tablet). Patients start at the lowest dose and increase gradually under their prescriber's guidance. The titration approach is standard for GLP-1s to minimize GI side effects.
Unlike oral Wegovy (which must be taken on an empty stomach with ≤4 oz of water and no food for 30 minutes after), Foundayo can be taken any time of day, with or without food or water. For patients whose adherence to oral Wegovy's strict timing was the problem — not the medication itself — Foundayo may remove the key friction point.
Cost and Access
Lilly has priced Foundayo aggressively to compete with both injectable GLP-1s and Novo's oral Wegovy:
- Commercial insurance with savings card: as little as $25/month
- LillyDirect self-pay (lowest dose): $149/month
- LillyDirect self-pay (higher doses): up to $399/month
- Medicare Part D (eligible enrollees): as little as $50/month beginning July 1, 2026
Foundayo became available via LillyDirect immediately on approval, with shipping beginning April 6, 2026. Broad availability through U.S. retail pharmacies and telehealth providers was planned shortly after.
How It Fits in the Treatment Landscape
| Medication | Format | Avg. Weight Loss | Food/Water Rules |
|---|---|---|---|
| Foundayo (orforglipron) | Daily pill | ~12% | None — any time of day |
| Oral Wegovy 25 mg | Daily pill | ~17% | Empty stomach, limited water |
| Wegovy (semaglutide) | Weekly injection | ~15% | N/A |
| Zepbound (tirzepatide) | Weekly injection | ~20% | N/A |
The tradeoff is clear: Foundayo offers the most convenient format with the lowest efficacy ceiling among the major options. For patients who would refuse injections entirely — or who struggled with oral Wegovy's timing constraints — the oral option may be the difference between taking medication and not taking any.
Looking for a GLP-1 provider?
Licensed telehealth platforms offering semaglutide, tirzepatide, and now oral options.
Questions to Ask Your Provider
- Is Foundayo's expected weight-loss ceiling enough to meet my clinical goals, or would an injectable be more appropriate?
- If I'm currently on a weekly injection, what's the rationale for switching?
- How will we handle titration if side effects are an issue?
- Does my insurance cover Foundayo, and under what tier?
- If I can't afford Foundayo, what are the compounded or bridge options?
The Bottom Line
Foundayo is a meaningful addition to the GLP-1 landscape — not because it outperforms injectables, but because it removes the adherence and access barriers that kept many patients out of treatment entirely. The $25 savings card price and lack of food-timing restrictions make it the most accessible branded GLP-1 yet. For the right patient, convenience and consistent adherence may matter more than the 3–8 percentage-point efficacy gap versus injections. For others, the injectable route remains the stronger clinical choice.